Navigation Links
InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
Date:3/18/2009

BRISBANE, Calif., March 18 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that five abstracts from clinical and in-vitro studies of ITMN-191 (R7227) and the company's research programs related to the hepatitis C virus (HCV) have been accepted for presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL, April 22-26, 2009 in Copenhagen, Denmark). The abstracts are expected to be available at www.easl.ch. ITMN-191 is an HCV NS3 protease inhibitor, being developed in collaboration with Roche.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "Collectively, these abstracts demonstrate that ITMN-191 is a promising, potent antiviral compound for the treatment of HCV and underscore our company's continued progress in the research of new compounds for HCV patients."

Presentations of ITMN-191 Clinical Results

  • Antiviral Activity and Safety of ITMN-191 in Combination with Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis C Virus (HCV).
  • Incidence of Virologic Escape Observed During ITMN-191 Monotherapy is Genotype Dependent, Associated with a Specific NS3 Substitution, and Suppressed Upon Combination with Peginterferon alfa-2a/Ribavirin.

Additional InterMune Presentations at EASL

Titles of additional InterMune posters to be presented at EASL are as follows:

  • Combination of the NS3/4A Protease Inhibitor ITMN-191 with the Allosteric NS5B Polymerase Inhibitor ITMN-8020 Enhances Replicon Clearance and Reduces the Emergence of Drug Resistant Variants.
  • Discovery of Potent, Bioavailable HCV NS3/4A Inhibitors that Display Unimpaired Activity Against an NS3 Sequence Variant Associated with Resistance to Linear Tetrapeptides and Macrocyclic Inhibitors.
  • A Mouse Model with Long Term Expression of Hepatitis C Virus NS3/4A Protease for the Pharmacokinetic and Pharmacodynamic (PK-PD) Study of HCV Protease Inhibitors

About EASL

The European Association for the Study of the Liver (EASL) is the leading European association in the field of liver research. EASL brings together clinicians and scientists interested in the liver, providing an outlet for networking and learning. The EASL Annual Meeting attracts more than 7,000 participants annually.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on pirfenidone analog ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in the summer of 2009, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 16, 2009 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulatory approval process; (ii) risks related to failure to achieve the clinical trial results required to commercialize our product candidates; and (iii) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
2. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
3. InterMune Announces Issuance of U.S. Patent for ITMN-191
4. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
6. InterMune to Present at J.P. Morgan Healthcare Conference
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
9. InterMune to Release Third Quarter 2008 Financial Results on November 6
10. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
11. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
Breaking Biology News(10 mins):